A positive correlation between BTG3 expression and the post-progression survival rate was observed in all ovarian cancer patients, or G1-3, G 2-3, Grade3 or suboptimal cancer patients (Figure 4D, p < 0.05). The gene discussed is BTG3; the disease is cancer.